LARIDER RUFFIN: Open Payments
NPI 1861785099 · LINWOOD, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$278 in 11 payments from 6 companies in 2025. Trend: 2023 $39 · 2024 $151 · 2025 $278
Food & beverage: $248Long term medical supply or device loan: $30
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 1 | $99 |
| E.R. Squibb & Sons, L.L.C. | 5 | $82 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Abbott Laboratories | 1 | $30 |
| ABBVIE INC. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
Products named: Ozempic, COBENFY, AUSTEDO XR, FREESTYLE INSULINX, VRAYLAR, REXULTI.
Industry payments across NJ — which companies pay providers there.
